Jason D Roberts1, Thomas A Dewland1, David V Glidden2, Thomas J Hoffmann3, Dan E Arking4, Lin Y Chen5, Bruce M Psaty6, Jeffrey E Olgin1, Alvaro Alonso7, Susan R Heckbert8, Gregory M Marcus1. 1. Section of Cardiac Electrophysiology, Division of Cardiology, Department of Medicine, University of California San Francisco, San Francisco, CA. 2. Departments of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA. 3. Departments of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; Institute for Human Genetics, University of California San Francisco, San Francisco, CA. 4. McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD. 5. Department of Medicine, Cardiovascular Division, University of Minnesota, Minneapolis, MN. 6. Cardiovascular Health Research Unit, University of Washington, Seattle, WA; Departments of Medicine and Health Services, University of Washington, Seattle, WA; Group Health Research Institute, Group Health, Seattle, WA. 7. Division of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN. 8. Cardiovascular Health Research Unit, University of Washington, Seattle, WA; Group Health Research Institute, Group Health, Seattle, WA; Department of Epidemiology, University of Washington, Seattle, WA.
Abstract
BACKGROUND: Renin-angiotensin system (RAS) inhibition via angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce the risk of developing atrial fibrillation (AF) in certain populations, but the evidence is conflicting. Recent genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with AF, potentially identifying clinically relevant subtypes of the disease. We sought to investigate the impact of carrier status of 9 AF-associated SNPs on the efficacy of RAS inhibition for the primary prevention of AF. METHODS: We performed SNP-RAS inhibitor interaction testing with unadjusted and adjusted Cox proportional hazards models using a discovery (Cardiovascular Health Study) and a replication (Atherosclerosis Risk in Communities) cohort. Additive genetic models were used for the SNP analyses, and 2-tailed P values <.05 were considered statistically significant. RESULTS: Among 2,796 Cardiovascular Health Study participants, none of the 9 a priori identified candidate SNPs exhibited a significant SNP-drug interaction. Two of the 9 SNPs, rs2106261 (16q22) and rs6666258 (1q21), revealed interaction relationships that neared statistical significance (with point estimates in the same direction for angiotensin-converting enzyme inhibitor only and angiotensin II receptor blocker only analyses), but neither association could be replicated among 8,604 participants in Atherosclerosis Risk in Communities. CONCLUSIONS: Our study failed to identify AF-associated SNP genetic subtypes of AF that derive increased benefit from upstream RAS inhibition for AF prevention. Future studies should continue to investigate the impact of genotype on the response to AF treatment strategies in an effort to develop personalized approaches to therapy and prevention.
BACKGROUND:Renin-angiotensin system (RAS) inhibition via angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers may reduce the risk of developing atrial fibrillation (AF) in certain populations, but the evidence is conflicting. Recent genome-wide association studies have identified several single nucleotide polymorphisms (SNPs) associated with AF, potentially identifying clinically relevant subtypes of the disease. We sought to investigate the impact of carrier status of 9 AF-associated SNPs on the efficacy of RAS inhibition for the primary prevention of AF. METHODS: We performed SNP-RAS inhibitor interaction testing with unadjusted and adjusted Cox proportional hazards models using a discovery (Cardiovascular Health Study) and a replication (Atherosclerosis Risk in Communities) cohort. Additive genetic models were used for the SNP analyses, and 2-tailed P values <.05 were considered statistically significant. RESULTS: Among 2,796 Cardiovascular Health Study participants, none of the 9 a priori identified candidate SNPs exhibited a significant SNP-drug interaction. Two of the 9 SNPs, rs2106261 (16q22) and rs6666258 (1q21), revealed interaction relationships that neared statistical significance (with point estimates in the same direction for angiotensin-converting enzyme inhibitor only and angiotensin II receptor blocker only analyses), but neither association could be replicated among 8,604 participants in Atherosclerosis Risk in Communities. CONCLUSIONS: Our study failed to identify AF-associated SNP genetic subtypes of AF that derive increased benefit from upstream RAS inhibition for AF prevention. Future studies should continue to investigate the impact of genotype on the response to AF treatment strategies in an effort to develop personalized approaches to therapy and prevention.
Authors: Yoko Miyasaka; Marion E Barnes; Bernard J Gersh; Stephen S Cha; Kent R Bailey; Walter P Abhayaratna; James B Seward; Teresa S M Tsang Journal: Circulation Date: 2006-07-03 Impact factor: 29.690
Authors: Kristen K Patton; Eran S Zacks; Joseph Y Chang; Marisa A Shea; Jeremy N Ruskin; Calum A Macrae; Patrick T Ellinor Journal: Pacing Clin Electrophysiol Date: 2005-07 Impact factor: 1.976
Authors: Jeff S Healey; Adrian Baranchuk; Eugene Crystal; Carlos A Morillo; Michael Garfinkle; Salim Yusuf; Stuart J Connolly Journal: J Am Coll Cardiol Date: 2005-06-07 Impact factor: 24.094
Authors: Denis Roy; Mario Talajic; Stanley Nattel; D George Wyse; Paul Dorian; Kerry L Lee; Martial G Bourassa; J Malcolm O Arnold; Alfred E Buxton; A John Camm; Stuart J Connolly; Marc Dubuc; Anique Ducharme; Peter G Guerra; Stefan H Hohnloser; Jean Lambert; Jean-Yves Le Heuzey; Gilles O'Hara; Ole Dyg Pedersen; Jean-Lucien Rouleau; Bramah N Singh; Lynne Warner Stevenson; William G Stevenson; Bernard Thibault; Albert L Waldo Journal: N Engl J Med Date: 2008-06-19 Impact factor: 91.245
Authors: Gregory M Marcus; Lisa M Smith; Eric Vittinghoff; Zian H Tseng; Nitish Badhwar; Byron K Lee; Randall J Lee; Melvin M Scheinman; Jeffrey E Olgin Journal: Heart Rhythm Date: 2008-02-16 Impact factor: 6.343
Authors: Daniel F Gudbjartsson; David O Arnar; Anna Helgadottir; Solveig Gretarsdottir; Hilma Holm; Asgeir Sigurdsson; Adalbjorg Jonasdottir; Adam Baker; Gudmar Thorleifsson; Kristleifur Kristjansson; Arnar Palsson; Thorarinn Blondal; Patrick Sulem; Valgerdur M Backman; Gudmundur A Hardarson; Ebba Palsdottir; Agnar Helgason; Runa Sigurjonsdottir; Jon T Sverrisson; Konstantinos Kostulas; Maggie C Y Ng; Larry Baum; Wing Yee So; Ka Sing Wong; Juliana C N Chan; Karen L Furie; Steven M Greenberg; Michelle Sale; Peter Kelly; Calum A MacRae; Eric E Smith; Jonathan Rosand; Jan Hillert; Ronald C W Ma; Patrick T Ellinor; Gudmundur Thorgeirsson; Jeffrey R Gulcher; Augustine Kong; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nature Date: 2007-07-01 Impact factor: 49.962
Authors: Julian Little; Julian P T Higgins; John P A Ioannidis; David Moher; France Gagnon; Erik von Elm; Muin J Khoury; Barbara Cohen; George Davey-Smith; Jeremy Grimshaw; Paul Scheet; Marta Gwinn; Robin E Williamson; Guang Yong Zou; Kim Hutchings; Candice Y Johnson; Valerie Tait; Miriam Wiens; Jean Golding; Cornelia van Duijn; John McLaughlin; Andrew Paterson; George Wells; Isabel Fortier; Matthew Freedman; Maja Zecevic; Richard King; Claire Infante-Rivard; Alex Stewart; Nick Birkett Journal: Eur J Clin Invest Date: 2009-04 Impact factor: 4.686